120 related articles for article (PubMed ID: 27912079)
21. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
22. Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy.
Trottier B; Machouf N; Thomas R; Gallant S; Longpré D; Vézina S; Boissonnault M; Lavoie S; Legault D; Dion H; Nguyen VK
HIV Clin Trials; 2012; 13(6):335-42. PubMed ID: 23195671
[TBL] [Abstract][Full Text] [Related]
23. Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression.
Chrdle A; Jerhotová Z; Vacík M; Linka M; Chmelík V
Int J STD AIDS; 2019 Jan; 30(1):94-98. PubMed ID: 30231834
[TBL] [Abstract][Full Text] [Related]
24. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse.
Choudhary SK; Rezk NL; Ince WL; Cheema M; Zhang L; Su L; Swanstrom R; Kashuba AD; Margolis DM
J Virol; 2009 Aug; 83(16):8254-8. PubMed ID: 19494021
[TBL] [Abstract][Full Text] [Related]
25. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
26. Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
van Dam PM; van Geffen MW; Havenith TR; Posthouwer D
Antivir Ther; 2018; 23(6):549-552. PubMed ID: 29533918
[TBL] [Abstract][Full Text] [Related]
27. Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy.
Lombardi F; Belmonti S; Borghetti A; Ciccullo A; Fabbiani M; Di Giambenedetto S
Infez Med; 2020 Sep; 28(3):461-463. PubMed ID: 32920587
[TBL] [Abstract][Full Text] [Related]
28. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
29. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
30. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
[TBL] [Abstract][Full Text] [Related]
31. Modeling HIV-1 Mucosal Transmission and Prevention in Humanized Mice.
Veselinovic M; Charlins P; Akkina R
Methods Mol Biol; 2016; 1354():203-20. PubMed ID: 26714714
[TBL] [Abstract][Full Text] [Related]
32. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
33. Nukes alone.
TreatmentUpdate; 1999 Aug; 11(6):1-2. PubMed ID: 11366932
[TBL] [Abstract][Full Text] [Related]
34. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
35. Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen.
Chini M; Tsoupras AB; Mangafas N; Tsogas N; Papakonstantinou VD; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
Int J Immunopathol Pharmacol; 2012; 25(1):247-58. PubMed ID: 22507337
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Khanlou H; Farthing C
AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
[No Abstract] [Full Text] [Related]
37. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B;
AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238
[TBL] [Abstract][Full Text] [Related]
38. Abacavir arm stopped in clinical trial.
James JS
AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475
[TBL] [Abstract][Full Text] [Related]
39. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Kuritzkes DR; Ribaudo HJ; Squires KE; Koletar SL; Santana J; Riddler SA; Reichman R; Shikuma C; Meyer WA; Klingman KL; Gulick RM;
J Infect Dis; 2007 Apr; 195(8):1169-76. PubMed ID: 17357053
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Maggiolo F; Roat E; Pinti M; Nasi M; Gibellini L; De Biasi S; Airoldi M; Ravasio V; Mussini C; Suter F; Cossarizza A
Antivir Ther; 2010; 15(1):51-9. PubMed ID: 20167991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
